SK8252001A3 - Controlled release formulation of divalproex sodium - Google Patents

Controlled release formulation of divalproex sodium Download PDF

Info

Publication number: SK8252001A3
Authority: SK; Slovakia
Prior art keywords: weight; particle size; controlled release; weight percent; silica
Prior art date: 1998-12-18

Application number

SK825-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Yihong Qui

Richard P Poska

Howard S Cheskin

J Daniel Bollinger

Kevin R Engh

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-18

Filing date

1999-12-09

Publication date

2001-12-03

1998-12-18 Priority claimed from US09/216,650 external-priority patent/US6419953B1/en

1999-12-09 Application filed by Abbott Lab filed Critical Abbott Lab

2001-12-03 Publication of SK8252001A3 publication Critical patent/SK8252001A3/sk

Links

239000000203 mixture Substances 0.000 title claims abstract description 77
238000013270 controlled release Methods 0.000 title claims abstract description 38
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 title claims abstract description 37
229940028937 divalproex sodium Drugs 0.000 title claims abstract description 27
238000009472 formulation Methods 0.000 title abstract description 39
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims abstract description 75
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 68
239000002245 particle Substances 0.000 claims abstract description 41
229960000604 valproic acid Drugs 0.000 claims abstract description 40
239000000377 silicon dioxide Substances 0.000 claims abstract description 31
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 23
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 23
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 23
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 23
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 21
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 21
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 19
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 17
239000008101 lactose Substances 0.000 claims abstract description 17
239000002552 dosage form Substances 0.000 claims abstract description 14
238000000034 method Methods 0.000 claims abstract description 14
239000004480 active ingredient Substances 0.000 claims abstract description 12
150000002148 esters Chemical class 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 9
OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 claims abstract description 8
229960001930 valpromide Drugs 0.000 claims abstract description 8
239000007916 tablet composition Substances 0.000 claims abstract description 7
206010015037 epilepsy Diseases 0.000 claims abstract description 5
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 10
239000008187 granular material Substances 0.000 claims description 37
238000007906 compression Methods 0.000 claims description 11
230000006835 compression Effects 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 9
238000002156 mixing Methods 0.000 claims description 8
239000004615 ingredient Substances 0.000 claims description 7
239000008240 homogeneous mixture Substances 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
238000001035 drying Methods 0.000 claims description 4
238000007580 dry-mixing Methods 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
238000000227 grinding Methods 0.000 claims description 2
238000011287 therapeutic dose Methods 0.000 claims description 2
238000012216 screening Methods 0.000 claims 1
235000012239 silicon dioxide Nutrition 0.000 abstract description 5
239000003814 drug Substances 0.000 description 38
239000003826 tablet Substances 0.000 description 38
229940079593 drug Drugs 0.000 description 35
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
230000000694 effects Effects 0.000 description 11
238000005469 granulation Methods 0.000 description 10
230000003179 granulation Effects 0.000 description 10
230000036470 plasma concentration Effects 0.000 description 10
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 9
229960001375 lactose Drugs 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
229920003091 Methocel™ Polymers 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
238000005299 abrasion Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000000654 additive Substances 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000463 material Substances 0.000 description 4
229960001866 silicon dioxide Drugs 0.000 description 4
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 4
229940084026 sodium valproate Drugs 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000001856 Ethyl cellulose Substances 0.000 description 3
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
235000019325 ethyl cellulose Nutrition 0.000 description 3
229920001249 ethyl cellulose Polymers 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
229940052586 pro 12 Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000001961 anticonvulsive agent Substances 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
229940057948 magnesium stearate Drugs 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000010079 rubber tapping Methods 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
208000034423 Delivery Diseases 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000002485 combustion reaction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000004049 embossing Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000013563 matrix tablet Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000004311 natamycin Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000233 poly(alkylene oxides) Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
-1 propyl methyl Chemical group 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960004029 silicic acid Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000007921 solubility assay Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK825-2001A 1998-12-18 1999-12-09 Controlled release formulation of divalproex sodium SK8252001A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/216,650 US6419953B1 (en)	1998-12-18	1998-12-18	Controlled release formulation of divalproex sodium
US12155799P	1999-02-25	1999-02-25
PCT/US1999/029204 WO2000037055A1 (fr)	1998-12-18	1999-12-09	Preparation a liberation controlee de divalproex sodium

Publications (1)

Publication Number	Publication Date
SK8252001A3 true SK8252001A3 (en)	2001-12-03

Family

ID=26819594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK825-2001A SK8252001A3 (en)	1998-12-18	1999-12-09	Controlled release formulation of divalproex sodium

Country Status (25)

Country	Link
EP (1)	EP1140034B1 (fr)
JP (1)	JP2003513882A (fr)
KR (1)	KR20010101295A (fr)
CN (1)	CN1335769A (fr)
AR (1)	AR021443A1 (fr)
AT (1)	ATE254907T1 (fr)
AU (1)	AU2478900A (fr)
BG (1)	BG105665A (fr)
BR (1)	BR9916361A (fr)
CA (1)	CA2330480C (fr)
CO (1)	CO5160287A1 (fr)
CZ (1)	CZ20012201A3 (fr)
DE (1)	DE69913197T2 (fr)
DK (1)	DK1140034T3 (fr)
ES (1)	ES2212667T3 (fr)
HK (1)	HK1043043B (fr)
HU (1)	HUP0105463A3 (fr)
IL (1)	IL143407A0 (fr)
NO (1)	NO20012986L (fr)
PL (1)	PL356899A1 (fr)
PT (1)	PT1140034E (fr)
SI (1)	SI20624A (fr)
SK (1)	SK8252001A3 (fr)
TW (1)	TW585788B (fr)
WO (1)	WO2000037055A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6419953B1 (en)	1998-12-18	2002-07-16	Abbott Laboratories	Controlled release formulation of divalproex sodium
US20020025341A1 (en) *	1998-12-18	2002-02-28	Yihong Qiu	Controlled release formulation of divalproex sodium
US6528090B2 (en)	1998-12-18	2003-03-04	Abbott Laboratories	Controlled release formulation of divalproex sodium
US6511678B2 (en)	1998-12-18	2003-01-28	Abbott Laboratories	Controlled release formulation of divalproex sodium
US6713086B2 (en)	1998-12-18	2004-03-30	Abbott Laboratories	Controlled release formulation of divalproex sodium
WO2002051402A1 (fr) *	2000-12-22	2002-07-04	Abbott Laboratories	Controlled release formulation of divalproex sodium
ES2281527T3 (es) *	2001-05-25	2007-10-01	Cephalon, Inc.	Formulaciones farmaceuticas solidas que comprenden modafinilo.
US7229644B2 (en) *	2002-05-23	2007-06-12	Cephalon, Inc.	Pharmaceutical formulations of modafinil
US20040005357A1 (en) *	2002-07-03	2004-01-08	Sherman Bernard Charles	Extended-release tablets comprising divalproex sodium
US20040048931A1 (en)	2002-07-12	2004-03-11	Craig Heacock	Modafinil pharmaceutical compositions
US20040116532A1 (en)	2002-09-13	2004-06-17	Craig Heacock	Pharmaceutical formulations of modafinil
MXPA05009886A (es) *	2003-03-14	2006-05-04	Nirmal Mulye	Un proceso para preparar tabletas de liberacion constante.
HUP0301537A3 (en) *	2003-06-03	2005-07-28	Egis Gyogyszergyar Nyilvanosan	Deramcyclane fumarate tablets and process for producing them
US7713550B2 (en)	2004-06-15	2010-05-11	Andrx Corporation	Controlled release sodium valproate formulation
WO2006025029A2 (fr) *	2004-08-31	2006-03-09	Ranbaxy Laboratories Limited	Composition de divalproex a liberation prolongee
BRPI0606932A2 (pt) *	2005-01-26	2009-07-28	Elan Pharma Int Ltd	formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação
US20070202164A1 (en) *	2006-02-28	2007-08-30	Hutchison Medipharma Enterprises Limited	Andrographis Extract Formulations
US8952060B2 (en) *	2009-05-12	2015-02-10	Amorepacific Corporation	Composition for preventing hair loss or for stimulating hair growth
WO2012121862A2 (fr) *	2011-02-17	2012-09-13	University Of Florida Research Foundation	Composés dérivés de l'acide valproïque
CN102138911B (zh) *	2011-03-28	2012-12-12	孙卫东	一种双丙戊酸钠缓释片及其制备方法
CN102895201B (zh) *	2011-07-26	2014-09-10	北大方正集团有限公司	丙戊酸半钠片剂及其制备方法
WO2014078435A1 (fr)	2012-11-14	2014-05-22	W. R. Grace & Co.-Conn.	Compositions contenant un matériau biologiquement actif et un oxyde inorganique non ordonné
CN105012264B (zh) *	2014-04-16	2019-11-29	四川科瑞德制药股份有限公司	丙戊酸钠缓释片及其制备工艺和用途
CN106389368B (zh) *	2015-07-29	2021-11-12	四川科瑞德制药股份有限公司	一种丙戊酸钠缓释制剂及其制备工艺和用途
CN105456218A (zh) *	2015-12-07	2016-04-06	黑龙江省智诚医药科技有限公司	一种丙戊酸镁缓释片及其制备方法
CN107028907B (zh) *	2016-02-04	2021-05-14	成都康弘药业集团股份有限公司	一种双丙戊酸钠缓释片
CN114681419A (zh) *	2020-12-28	2022-07-01	湖南省湘中制药有限公司	一种丙戊酰胺缓释片的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5009897A (en) *	1988-06-24	1991-04-23	Abbott Laboratories	Pharmaceutical granules and tablets made therefrom
US5169642A (en) *	1988-06-24	1992-12-08	Abbott Laboratories	Sustained-release drug dosage units
FR2643556B1 (fr) *	1989-02-27	1993-03-05	Sanofi Sa	Composition pharmaceutique a liberation prolongee d'acide valproique
IL96311A (en) *	1989-12-01	1995-05-26	Abbott Lab	Medications with delayed release
US5075114A (en) *	1990-05-23	1991-12-24	Mcneil-Ppc, Inc.	Taste masking and sustained release coatings for pharmaceuticals
TW224049B (fr) *	1991-12-31	1994-05-21	Sunkyong Ind Ltd
TW222585B (fr) *	1992-09-11	1994-04-21	Hoechst Ag
JP3552285B2 (ja) *	1993-08-03	2004-08-11	三菱化学株式会社	経口コレステロール低下剤
GB9501127D0 (en) *	1995-01-20	1995-03-08	Wellcome Found	Tablet
CA2216215A1 (fr) *	1997-04-05	1998-10-05	Isa Odidi	Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie

1999
- 1999-12-09 SK SK825-2001A patent/SK8252001A3/sk unknown
- 1999-12-09 PT PT99968104T patent/PT1140034E/pt unknown
- 1999-12-09 CA CA002330480A patent/CA2330480C/fr not_active Expired - Fee Related
- 1999-12-09 ES ES99968104T patent/ES2212667T3/es not_active Expired - Lifetime
- 1999-12-09 PL PL99356899A patent/PL356899A1/xx not_active Application Discontinuation
- 1999-12-09 EP EP99968104A patent/EP1140034B1/fr not_active Expired - Lifetime
- 1999-12-09 JP JP2000589166A patent/JP2003513882A/ja active Pending
- 1999-12-09 AU AU24789/00A patent/AU2478900A/en not_active Abandoned
- 1999-12-09 HU HU0105463A patent/HUP0105463A3/hu unknown
- 1999-12-09 CZ CZ20012201A patent/CZ20012201A3/cs unknown
- 1999-12-09 DE DE69913197T patent/DE69913197T2/de not_active Expired - Lifetime
- 1999-12-09 IL IL14340799A patent/IL143407A0/xx unknown
- 1999-12-09 SI SI9920100A patent/SI20624A/sl not_active IP Right Cessation
- 1999-12-09 AT AT99968104T patent/ATE254907T1/de active
- 1999-12-09 DK DK99968104T patent/DK1140034T3/da active
- 1999-12-09 CN CN99814629A patent/CN1335769A/zh active Pending
- 1999-12-09 KR KR1020017007649A patent/KR20010101295A/ko not_active Ceased
- 1999-12-09 WO PCT/US1999/029204 patent/WO2000037055A1/fr not_active Application Discontinuation
- 1999-12-09 BR BR9916361-6A patent/BR9916361A/pt not_active Application Discontinuation
- 1999-12-15 CO CO99078240A patent/CO5160287A1/es unknown
- 1999-12-17 AR ARP990106552A patent/AR021443A1/es not_active Application Discontinuation
- 1999-12-18 TW TW088122338A patent/TW585788B/zh not_active IP Right Cessation
2001
- 2001-06-15 NO NO20012986A patent/NO20012986L/no not_active Application Discontinuation
- 2001-07-03 BG BG105665A patent/BG105665A/bg unknown
2002
- 2002-03-28 HK HK02102407.1A patent/HK1043043B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2330480A1 (fr)	2000-06-29
IL143407A0 (en)	2002-04-21
EP1140034A1 (fr)	2001-10-10
BR9916361A (pt)	2002-11-05
HUP0105463A2 (hu)	2002-05-29
KR20010101295A (ko)	2001-11-14
CO5160287A1 (es)	2002-05-30
AR021443A1 (es)	2002-07-17
NO20012986L (no)	2001-08-15
DE69913197D1 (de)	2004-01-08
BG105665A (bg)	2002-03-29
CZ20012201A3 (cs)	2001-09-12
CA2330480C (fr)	2002-05-21
HK1043043A1 (en)	2002-09-06
SI20624A (sl)	2002-02-28
WO2000037055A1 (fr)	2000-06-29
AU2478900A (en)	2000-07-12
EP1140034B1 (fr)	2003-11-26
CN1335769A (zh)	2002-02-13
DE69913197T2 (de)	2004-09-02
TW585788B (en)	2004-05-01
PL356899A1 (en)	2004-07-12
NO20012986D0 (no)	2001-06-15
ES2212667T3 (es)	2004-07-16
DK1140034T3 (da)	2004-03-08
PT1140034E (pt)	2004-03-31
HUP0105463A3 (en)	2003-03-28
JP2003513882A (ja)	2003-04-15
ATE254907T1 (de)	2003-12-15
HK1043043B (zh)	2004-09-10

Publication	Publication Date	Title
SK8252001A3 (en)	2001-12-03	Controlled release formulation of divalproex sodium
CA2304110C (fr)	2004-03-30	Comprime de theophylline a liberation prolongee
US5811126A (en)	1998-09-22	Controlled release matrix for pharmaceuticals
US4970075A (en)	1990-11-13	Controlled release bases for pharmaceuticals
EP0253104B1 (fr)	1991-04-10	Supports pour la libération programmée de produits pharmaceutiques
US6528091B1 (en)	2003-03-04	Controlled release formulation of divalproex sodium
JP5420590B2 (ja)	2014-02-19	ｐＨ非依存延長放出性医薬組成物
JP4438268B2 (ja)	2010-03-24	薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
AU2003240164A1 (en)	2003-12-22	Extended release formulation of divalproex sodium
AU2009318979B2 (en)	2014-12-18	Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine
US20070160667A1 (en)	2007-07-12	Controlled release formulation of divalproex sodium
EP1815850A1 (fr)	2007-08-08	Formulation à libération contrôlée comprenant acide valproique et ses dérivés
WO2007081341A1 (fr)	2007-07-19	Formule à libération contrôlée d'acide divalproïque et ses dérivés
MXPA01006202A (es)	2002-05-09	Formulacion de liberacion controlada de sodio de divalproex
AU2004210543A1 (en)	2004-10-07	Controlled release formulation of divalproex sodium
WO2006025029A2 (fr)	2006-03-09	Composition de divalproex a liberation prolongee